Recent Company News

• 02:36 AM ET Aug 24, 2026
  

  Bayer AG announces sevabertinib approval in Japan for patients with HER2-mutant non-small cell lung cancer (€48.04, 0.00)

• 02:21 PM ET Aug 21, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 23-Aug

• 09:04 AM ET Aug 21, 2026
  

  MustGrow receives first milestone payment from Bayer AG (BAYN.GR) (7:00 ET) (C$0.44, 0.00)

• 08:11 AM ET Aug 20, 2026
  

  Bayer AG announces 11 oral presentations across cardiovascular, kidney, and secondary stroke prevention programs will be featured at ESC Congress 2026 in Munich, Germany, from August 28-31, 2026 (€48.50, -0.51)

• 02:32 PM ET Aug 17, 2026
  

  Bayer AG announces LYNKUET (elinzanetant) receives expanded market authorization in Canada for treatment of moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy (AET) related to breast cancer (€47.90, 0.00)

• 11:25 AM ET Aug 12, 2026
  

  StreetAccount ESG Research Round Up

• 02:30 AM ET Aug 06, 2026
  

  European macro headlines:

• 04:14 AM ET Aug 05, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 08:39 PM ET Aug 04, 2026
  

  NICE recommends Bayer's Kerendia to treat chronic heart failure with preserved or mildly reduced ejection fraction (€48.25, 0.00)